Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-42160443 in Postherpetic and Post-traumatic Neuralgia
NCT00964990Phase 2Terminated
- Sponsor
- Johnson & Johnson
- Start
- Sep 2009
- Primary completion
- Jul 2011
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of fulranumab in postherpetic neuralgia (PHN), post-traumatic neuralgia, sponsored by Johnson & Johnson. Started Sep 2009; status: terminated.
02
Drugs
fulranumab
03
Conditions
postherpetic neuralgia (PHN)post-traumatic neuralgia
Beyond the preview
Go deeper on NCT00964990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00964990.